- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Alkem Labs brands API business as Alkem Activa
By forging partnerships and collaborations, Alkem Activa aims to become a reliable supplier of high- quality APIs to pharmaceutical companies worldwide, contributing to the global healthcare ecosystem.
Mumbai: Alkem Laboratories Ltd. has announced the branding of their active pharmaceutical ingredients (API) business as Alkem Activa.
"Alkem Activa signifies a pivotal move for Alkem Laboratories as the company is dedicated to producing a diverse range of high-quality APIs that cater to the evolving needs of the pharmaceutical industry. Moreover, Alkem Activa reflects Alkem’s focus on sustainability and ensures that it remains at the forefront of API innovation through responsible practices. It is poised to introduce numerous APIs, further bolstering the Alkem's robust portfolio," the company stated.
Additionally, Alkem Activa plans to expand its capacity, incorporating cutting-edge technologies like biocatalytic and continuous manufacturing technologies to consolidate its position in this field. By forging partnerships and collaborations, Alkem Activa aims to become a reliable supplier of high- quality APIs to pharmaceutical companies worldwide, contributing to the global healthcare ecosystem.
Speaking about the company’s vision, Mr. Sandeep Singh - Managing Director of Alkem, said, “We mark a significant chapter in our journey. Alkem Activa represents our renewed commitment to API excellence, innovation, and global outreach. With our tagline, 'Innovative. Reliable. Sustainable,' we signify our determination to propel Alkem Activa into the forefront of the API market with sustainability at the core of our operations.”
“We envision Alkem Activa as a key contributor to healthcare solutions globally,” Sandeep Singh affirmed. “Our aim is to strengthen our position in the API market, enhance accessibility to quality pharmaceutical ingredients, and shape the future of healthcare together with our partners.”
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, Ophthalmology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
Read also: Alkem Gets CDSCO Panel Nod to Study Antidiabetic FDC Drug
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story